Antimicrobial drug pipelines have been presented the annual congress (ECCMID) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).
Small and innovative companies, with products in early stages of development, shared some of their novel approaches and antimicrobial therapies during a dedicated session at the event in Amsterdam.
Some of these emerging biotech companies and start-ups are filling the gap left by big pharma’s continuing move away from the development of antibacterial treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze